STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

Vyvgart didn’t outperform placebo in a trial of patients with Sjögren’s disease Drew Angerer/Getty Images Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Argenx said Thursday that its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren’s disease, a chronic autoimmune disorder. It’s an unusual setback for Argenx, which has racked up a series of wins in autoimmune disorders en route to becoming one of the world’s largest biotechs by market cap. Argenx’s stock slipped 13% Thursday morning. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe General Assignment Reporter Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.